NICE technology appraisal guidance No.25 on the use of gemcitabine for the treatment of pancreatic cancer

Following consultation, the majority of comments received have led to the agreement that the existing guidance on the use of gemcitabine for the treatment of pancreatic cancer (covering gemcitabine monotherapy) becomes static guidance.

The list of static technology appraisal guidance will be updated accordingly.